CLINICAL_TRIALS
trial_result
· 2014-04-03
Clinical Trial Update: CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma [Phase 2]
Summary
Phase 2 study of temsirolimus (CCI-779) for recurrent mantle cell lymphoma has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Mantle Cell Lymphoma | Phase 2 | Status: COMPLETED